Shy Therapeutics

Business Services · New York, United States · 1-10 Employees

View Company Info for Free

Overview

Headquarters

7 Dana Rd, Valhalla, New York, 10595, Un...

Revenue

<$5 Million

Industry

Business Services Research & Development
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1

About Shy Therapeutics

SHY Therapeutics is focused on advancing small molecule therapeutics that target ATPases and GTPases, addressing significant unmet medical needs in critical disease areas. The company boasts a proprietary portfolio of unique small molecules that serve as both target discovery tools and starting points for therapeutic design. With a patient-centric approach, SHY aims to develop first-in-class programs that exceed current standards of care, leveraging collaborations with experienced pharmaceutical and biotechnology partners for late-stage development. Their innovative strategy combines machine learning and traditional methods to create a groundbreaking path for therapeutic innovation.Explore more
Popular SearchesShy Therapeutics LLCSHY TherapeuticsShytherapeuticsSIC Code 87,873NAICS Code 54,541Show more

Shy Therapeutics Org Chart

YH
United States flag for contact location.

Co-Founder & Chief Executive Officer

PhoneEmail
SR
United States flag for contact location.

Chief Operating Officer

PhoneEmail

PhoneEmail
Get the full picture
Sign in to uncover key details.

Is Shy Therapeutics your ideal customer?

Let us give you the heads up on whether it's a good time to reach out

Recommended Actions

Compare Similar Companies to Shy Therapeutics

Compare insights from companies similar to Shy Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.

Company Name

Revenue

Number of Employees

Type

Funding

Founded In

Top Executive

Shy Therapeutics

<$5M
1-10
Private
-
2015
YH
Yaron HadariCo-Founder & CEO
<$5M
11-50
Private
<$5M
-
<$5M
11-50
Private
<$5M
2010
SL
Samantha LacyResearch Assistant
<$5M
11-50
Private
-
2009
N/A
<$5M
1-10
Private
$12M
2009
N/A
<$5M
1-10
Private
-
2022
N/A
<$5M
1-10
Private
-
2018
Alexey Tomilov, President & Chief Executive Officer at Bindkin Bio
Alexey TomilovPresident & CEO
Illustration of an envelope

Company Profile Activity

i

Among all Business Services companies

Low Activity

High Activity

Activity Insights

Shy Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.

What does this means?

Shy Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Shy Therapeutics.

Shy Therapeutics Tech Stack

A closer look at the technologies used by Shy Therapeutics

Top Business Services Companies

Frequently Asked Questions Regarding Shy Therapeutics

What is Shy Therapeutics's official website?
Shy Therapeutics's official website is www.shytherapeutics.com
What is Shy Therapeutics's Revenue?
Shy Therapeutics's revenue is <$5 Million
What is Shy Therapeutics's SIC code?
Shy Therapeutics's SIC: 87,873
What is Shy Therapeutics's NAICS code?
Shy Therapeutics's NAICS: 54,541
How many employees does Shy Therapeutics have?
Shy Therapeutics has 1-10 employees
What industry does Shy Therapeutics belong to?
Shy Therapeutics is in the industry of: Business Services, Research & Development
What is Shy Therapeutics competition?
Shy Therapeutics top competitors include: Ablexis, Bindkin Bio, Scaffold Therapeutics, Abzyme Therapeutics
What technology does Shy Therapeutics use?
Some of the popular technologies that Shy Therapeutics uses are: Squarespace Online Stores, Adobe Typekit, Microsoft 365, GoDaddy DNS
What does Shy Therapeutics do?

SHY Therapeutics is focused on advancing small molecule therapeutics that target ATPases and GTPases, addressing significant unmet medical needs in critical disease areas. The company boasts a proprietary portfolio of unique small molecules that serve as both target discovery tools and starting points for therapeutic design. With a patient-centric... approach, SHY aims to develop first-in-class programs that exceed current standards of care, leveraging collaborations with experienced pharmaceutical and biotechnology partners for late-stage development. Their innovative strategy combines machine learning and traditional methods to create a groundbreaking path for therapeutic innovation.Read More

Is Shy Therapeutics a public company?
Shy Therapeutics is private company therefore does not currently have an official ticker symbol
See more information about Shy Therapeutics

Get Started with ZoomInfo

Register for free

Sign Up for Free

Get started for free! No credit card needed. Enjoy up to 25 free contacts each month at no cost.
Elevate your prospecting to the next level

Supercharge Your Prospecting

Search ZoomInfo's database of 106M+ companies and 140M+ professionals to find your next lead.
Expand your business

Grow Your Business

Reveal both personal and business contact details, including emails and phone numbers, and close your most valuable buyers.